Optimization of a classical aromatase activity assay and application in normal, adenomatous and malignant breast parenchyma.
The tritium water release assay, originally described for the analysis of aromatase activity in placental tissue, was used to estimate aromatase activity in breast tissue samples. The lower activity in this tissue necessitates longer incubation times and thus optimization of the assay conditions. To prevent oxidative and proteolytic inactivation of aromatase, dithiothreitol and albumin were added to the incubation mixture. Extra NADPH, cofactor in the aromatase reaction, also improved reaction rate in placental incubations, but after approximately 120 min activity rapidly decreased. Inhibitors gradually produced during the incubation could explain this phenomenon. Quantitative gas chromatography-mass spectrometry (GC-MS) analyses of testosterone, oestradiol, oestrone and androstenedione after incubation with non-labelled androstenedione proved that a substantial amount of the substrate is converted into testosterone. Qualitative GC-MS steroid profiling of the incubation mixture demonstrated the presence of hydroxylated oestradiol and hydroxylated testosterone, produced during incubation, which could have caused partial aromatase inhibition. The adjusted assay was used to analyse 84 breast tissue samples, histologically classified as normal, adenoma or carcinoma. Aromatase activity was found in 56% of all samples and ranged from 0.6 to 26 pmol oestrogen/g protein per hour. Aromatase positivity was found in 80% of the normal samples, 56% of the adenoma samples and 48% of the carcinoma samples. Although carcinoma samples were less often aromatase positive than normal tissue samples (chi2 = 4.80; P < 0.050) there was no difference in absolute aromatase activity. Because no less than approximately 50% of the carcinomas contained aromatase activity and because of the non-routine character of the assay we conclude that it is justified to start aromatase inhibition therapy without previous knowledge of the aromatase status.
Dikkeschei
L D
LD
The Central Laboratory for Clinical Chemistry, University Hospital, Groningen, The Netherlands.
Wolthers
B G
BG
Bos-Zuur
I
I
de la Rivière
G B
GB
Nagel
G T
GT
van der Kolk
D A
DA
Willemse
P H
PH
D000236:Adenoma / Q000201:enzymology*; D000735:Androstenedione / Q000378:metabolism; D001141:Aromatase / Q000378:metabolism*; D001940:Breast / Q000201:enzymology*; D001943:Breast Neoplasms / Q000201:enzymology*; D002277:Carcinoma / Q000201:enzymology*; D004958:Estradiol / Q000378:metabolism; D004970:Estrone / Q000378:metabolism; D005260:Female; D006801:Humans; D007700:Kinetics; D009249:NADP / Q000378:metabolism; D010920:Placenta / Q000201:enzymology; D017698:Postmenopause; D017697:Premenopause; D012680:Sensitivity and Specificity; D013739:Testosterone / Q000378:metabolism
D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D004958:Estradiol; D009249:NADP; D001141:Aromatase